NemaGen Discoveries is an early-stage Rutgers University spinout company founded in 2019 by an expert in parasitology and immunology, Marc Siracusa. NemaGen aims to develop novel therapies for chronic inflammation and mast cell-related diseases. They investigated how the body naturally controls mast cell development during parasitic nematode infections, which allowed the identification of therapeutic targets for eliminating and preventing excessive inflammation. Thus, they aim to develop therapies that modulate the Mast cell development or function to mitigate inflammatory diseases. The main advantage of NemaGen’s approach is that it has the potential to be preventative, rather than just providing symptom management.

NemaGen Discoveries

Founded: 2022
Location: Princeton, NJ
Employee range: 1 - 10
Clinical stage: RD
Product link: https://nemagen.com/technology
Funding: $1M Seed 2022
Investors: FVCG

Short description:

Drug notes:

Long description:

Jobs: